Pulse Endovascular ReperFUSION for Acute Ischemic Stroke

NCT ID: NCT06052969

Last Updated: 2025-08-07

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-01
• Study Completion Date: 2026-03-15

Brief Summary

Prospective, multi-center, single-arm early feasibility study enrolling a minimum of 15 subjects at up to a minimum of 3 active investigational sites in the United States.

The subjects must be diagnosed with acute ischemic stroke (AIS), must be post-mechanical thrombectomy, will have had intravenous thrombolytics, and have a visible MCA, ACA or PCA occlusive clot on initial angiographic imaging.

Each subject will receive the Pulse NanoMED procedure after attempted neurovascular therapy to achieve better reperfusion.

Conditions

Acute Ischemic Stroke AIS; Cerebral Arterial Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group/Cohort

Subjects presenting to the emergency department with AIS, eligible for thrombolytic therapy, and with evidence of an occlusive clot by angiographic imaging will be considered for inclusion in the study. Post-thrombolytic therapy and mechanical thrombectomy eligible Subjects will receive the experimental NanoMED device.

Group Type: EXPERIMENTAL

Pulse NanoMED System

Intervention Type: DEVICE

The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.

Interventions

Pulse NanoMED System

The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. The participant provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the Institutional Review Board (IRB) or an acceptable patient surrogate.

2. The participant is ≥ 18 years old and less than 85 years old.

3. Patients with symptomatic large vessel occlusion (LVO) who undergo MT as part of their standard of care and have residual occlusion involving the anterior, middle or posterior cerebral arteries resulting in a eTICI score greater than 2b50 at the end of the procedure with three or less MT device passes.

4. Estimated delay to onset of rescue Pulse NanoMED MicroBead administration <9 hours from symptom onset, defined as the point in time the patient was last known well (LKW).

5. Post-MT and has had thrombolytic therapy <9 hours prior to the proposed start time of System therapy

6. No significant pre-stroke functional disability (modified Rankin scale 0-1)

7. Baseline NIHSS≥6

8. ASPECTS >6 on non-contrast CT (NCCT) scan if symptoms lasting <8 hours

9. CT-Perfusion (CTP) is optional, if performed, should demonstrate rCBF <30% lesion volume ≤70 mL.

10. Imaging should be obtained within 75 minutes of the onset of mechanical thrombectomy.

Exclusion Criteria

1. NIHSS score on admission >25

2. Use of carotid artery stents during the endovascular procedure requiring dual antiplatelet therapy

3. Female who is pregnant or lactating or has a positive pregnancy test at the time of admission

4. Current participation in another investigational drug or device treatment study

5. Known allergy or sensitivity to iron

6. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency

7. Known coagulopathy, INR >1.7, or use of novel anticoagulants <12h from symptom onset

8. Known Platelets <100,000

9. Known Renal Failure as defined by a serum creatinine >3.0 mg/dl (or 265.2 μmol/l) or glomerular Filtration Rate [GFR] <30

10. Subject who requires hemodialysis or peritoneal dialysis or who has a contraindication to angiogram for whatever reason

11. Any hemorrhage on CT/MRI

12. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal.

13. Suspicion of aortic dissection

14. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol.

15. History of life-threatening allergy (more than rash) to contrast medium

16. SBP >185mmHg or DBP >110mmHg refractory to treatment

17. Serious, advanced, terminal illness with anticipated life expectancy <6 months

18. Pre-existing neurological or psychiatric disease that would confound evaluation

19. Presumed vasculitis or septic embolization

20. Known sensitivity or allergy to contrast materials that cannot be previously treated properly

21. The subject takes Coumadin and its interruption could compromise their safety

22. Known allergy or contraindication to double antiplatelet treatment

23. Known hypersensitivity or contraindication to iron or polyethylene glycol-based agents

24. Known contraindication to MRI (examples include, but are not known, implantable cardioverter-defibrillator, pacemaker, clip-on or spiral aneurysm, neurostimulator)

25. The physical geometry of the subject that prevents the placement of the magnet

26. The subject has signs or symptoms of systemic infection/sepsis (temperature of ≥38.0 Celsius and/or white blood cell count of ≥12,000 cells/uL). If the subject has a localized infection, such as cellulitis or osteomyelitis, or the infection is properly treated and controlled, according to the discretion of the researcher, the patient can enroll

27. Known or suspected cardiovascular condition that causes a secondary or tertiary heart block, tachycardia-bradycardia syndrome, or symptomatic postural hypotension requiring medical intervention

28. Known or suspected symptomatic hemochromatosis or hemosiderosis

29. Known or suspected liver disease, such as hepatitis and/or cirrhosis

30. The subject has received iron replacement therapy or contrast for iron-based MRI in the previous 30 days

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Euphrates Vascular, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of South Carolina - Prisma

Columbia, South Carolina, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Kristen Hlozek, PhD

Role: CONTACT

kristen@euphratesvascular.com

857-334-0851

Facility Contacts

Souvik Sen, MD, MS, MPH

Role: primary

souvik.sen@uscmed.sc.edu

803-545-6073

Other Identifiers

G220131/S001

Identifier Type: OTHER

Identifier Source: secondary_id

MED-CLN-001P

Identifier Type: -

Identifier Source: org_study_id